40 studies found for:    Open Studies | "intraocular melanoma"
Show Display Options
Rank Status Study
1 Recruiting Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Stage I Intraocular Melanoma;   Stage IIA Intraocular Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIC Intraocular Melanoma
Interventions: Drug: Sunitinib;   Drug: Valproic Acid
2 Recruiting Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Stage IIA Uveal Melanoma;   Stage IIB Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma
Interventions: Radiation: External Beam Radiation Therapy;   Other: Laboratory Biomarker Analysis
3 Not yet recruiting Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
Conditions: Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
4 Unknown  Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies
5 Not yet recruiting Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Glembatumumab Vedotin;   Other: Laboratory Biomarker Analysis
6 Recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Conditions: Recurrent Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Akt Inhibitor GSK2141795;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
7 Recruiting Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
8 Recruiting Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Biological: autologous dendritic cells electroporated with mRNA
9 Not yet recruiting Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
Conditions: Macular Edema;   Cystoid Macular Edema;   Uveal Melanoma;   Radiation Maculopathy;   Radiation Retinopathy
Interventions: Drug: Ozurdex;   Drug: Bevacizumab
10 Unknown  Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma
Condition: Choroidal Melanoma, Diffuse
Intervention: Biological: Blood sampling
11 Recruiting BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma
Condition: Choroidal Nevi, Uveal Melanoma
Intervention:
12 Recruiting Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Condition: Uveal Melanoma, Monosomy 3 Positive, no Evidence for Metastases.
Intervention: Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA
13 Recruiting Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Condition: Uveal Melanoma
Intervention: Drug: crizotinib
14 Recruiting Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Radiation: Hypofractionated linear accelerator radiotherapy
15 Recruiting RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
16 Recruiting A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: MEK162
17 Unknown  Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
Condition: Intraocular Melanoma
Interventions: Drug: cisplatin;   Drug: sunitinib malate;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy
18 Recruiting TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy
Conditions: Exudative Retinal Detachment;   Uveal Melanoma
Interventions: Drug: Triamcinolone Acetonide;   Procedure: Transpupillary thermotherapy
19 Recruiting Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy
Condition: Uveal Melanoma
Interventions: Dietary Supplement: CITICOLINE;   Dietary Supplement: PLACEBO
20 Recruiting Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions: Genetic: DNA analysis;   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8;   Radiation: 131I-3F8

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years